De Facto Combinations: Why Some Patients Take Separate Generics Instead of FDCs

Every year, millions of people with chronic conditions like high blood pressure, diabetes, or HIV take multiple pills instead of a single combination pill. This isn’t a mistake - it’s a deliberate choice. These are called de facto combinations: when doctors prescribe separate generic drugs that, together, do the same job as a fixed-dose combination (FDC). But why? And is it really better?

What Exactly Is a De Facto Combination?

An FDC is a single pill that contains two or more active drugs in a fixed ratio. Think of it like a pre-mixed smoothie: you get all the ingredients in one go. Common examples include pills that combine amlodipine and valsartan for high blood pressure, or metformin and sitagliptin for type 2 diabetes.

A de facto combination is the opposite. Instead of one pill, you get two or three separate pills - each containing one drug. The combination still works, but it’s not officially approved as a combo. It’s created by the prescriber, not the manufacturer. This isn’t new. In fact, it’s become more common as generics flood the market.

Why Do Doctors Choose Separate Generics?

The biggest reason? Dose flexibility.

Let’s say a patient needs 5 mg of amlodipine and 80 mg of valsartan. The only FDC available comes in 10 mg/160 mg. That’s too much of both. If the doctor prescribes the FDC, the patient gets more drug than needed - which can cause side effects like dizziness or swelling. But if they prescribe separate generics, they can give exactly 5 mg of amlodipine and 80 mg of valsartan. No guesswork. No compromise.

This matters most for people with kidney or liver problems, older adults, or those on multiple medications. Their bodies process drugs differently. A one-size-fits-all FDC doesn’t work for them.

Cost is another factor. In some cases, buying two separate generics costs less than one FDC. For example, in India and parts of the U.S., generic amlodipine and losartan are so cheap that buying them separately saves patients $10-$20 a month compared to the branded FDC. That adds up over time.

The Hidden Risks Nobody Talks About

Here’s the catch: FDCs go through strict testing. Manufacturers must prove that the two drugs play well together - that they don’t break down in the pill, that they’re absorbed the same way in the body, and that the combo actually improves outcomes over taking each drug alone. The FDA and EMA require this.

De facto combinations? No such rules apply.

When you mix two generics from different manufacturers, you don’t know if they’re stable together. One might release too fast. Another might not dissolve properly. A 2020 FDA analysis found that 12.7% of generic drugs differ in bioavailability from their reference products. That means one patient might get 90% of the drug they need, while another gets 110%. That’s not just a technicality - it can lead to treatment failure or side effects.

And then there’s adherence. Every extra pill you have to take lowers your chance of sticking to the regimen. A 2018 study in Pediatrics found that each additional pill per day cuts adherence by about 16%. Patients on FDCs are 22% more likely to take their meds consistently than those on separate pills.

One Reddit user, u/HypertensionWarrior, wrote in March 2023: “My doctor switched me from a single Amlodipine/Benazepril pill to separate generics to save $15 a month. Now I forget which blue pill is which. I’ve missed doses twice already.”

When Separate Generics Actually Make Sense

It’s not all bad. For some patients, de facto combinations are the best - or only - option.

A 5-star Drugs.com review from January 2023 said: “As a diabetic with kidney issues, my doctor put me on separate Metformin and Sitagliptin generics because the FDC dosage wasn’t right for my kidney function. The separate pills let my doctor adjust doses precisely, which has kept my A1c at 6.2% for 18 months.”

That’s the sweet spot. When dosing needs to be fine-tuned - like in HIV treatment, where viral load and kidney function change over time - separate generics give doctors the control they need. The same goes for patients who are sensitive to side effects or need to taper one drug without touching the other.

A 2022 survey of 1,532 U.S. pharmacists found that 58% believed de facto combinations were appropriate in specific cases - especially for dose adjustments. But 72% also worried about medication errors.

What’s Being Done to Fix This?

Health systems are starting to respond.

PillPack by Amazon launched a Combination Therapy Support Program in 2021. It packages separate generics into color-coded, time-sorted blister packs and includes counseling. They reported a 41% drop in adherence issues among users.

Electronic health records are getting smarter. New systems now flag when a patient is on multiple drugs that could be combined into an FDC - or when they’re on a risky combo of generics with no clinical evidence.

Pharma companies are innovating too. AstraZeneca filed a patent in 2022 for a modular FDC that lets you swap doses like Lego bricks - keeping the convenience of a single pill while allowing flexibility. That could be the future.

What Should You Do?

If you’re on separate generics instead of an FDC:

• Ask your doctor: Is there an FDC that matches my dose?
• Ask your pharmacist: Are these generics compatible? Do they have the same release profile?
• Use a pill organizer. Color-coded, time-labeled ones work best.
• Set phone reminders for each pill. Don’t assume you’ll remember.
• Check your insurance. Sometimes, the FDC is covered at the same cost as separate pills.

If you’re a caregiver or clinician:

• Document the reason clearly: “De facto combination due to renal impairment requiring titration.”
• Use visual aids - charts, color codes, photos of pills.
• Review refills monthly. Are they being taken? Are there gaps?

The Bottom Line

De facto combinations aren’t inherently wrong. They’re a tool. Like a scalpel - useful in skilled hands, dangerous if misused.

For patients who need precise dosing, they’re lifesavers. For those who just need to take one pill a day? They’re a burden.

The trend is clear: as FDCs get smarter and more flexible, and as digital tools help manage pill regimens, the need for unmonitored de facto combinations will shrink. But they won’t disappear. Not yet. Not until every patient can get a pill that fits them - not the other way around.